NASDAQ
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
♥ 400 Thanks from members
Theravance Biopharma (TBPH) trades near $16.93 ahead of its pending $929 million acquisition by Zymeworks, featuring a $17 cash-plus-CVR deal structure, a solid Q2 2026 cash position of $388 million, and growing YUPELRI collaboration revenues.